MAP2K7 and lung carcinoma: Together these experiments demonstrate that ATM inactivation by shRNA knockdown or CRISPR/Cas9 knockout strongly sensitizes lung cancer cells to MEK inhibition even in the absence of KRAS or BRAF mutations.